

# Angela D M Kashuba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6784461/publications.pdf>

Version: 2024-02-01

106  
papers

5,620  
citations

126907

33  
h-index

82547

72  
g-index

111  
all docs

111  
docs citations

111  
times ranked

6241  
citing authors

#	ARTICLE	IF	CITATIONS
1	Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. <i>Pharmacotherapy</i> , 2023, 43, 638-649.	2.6	2
2	Editorial: New drugs for HIV: quo vadis?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 1-3.	3.8	1
3	Intracellular islatravir pharmacology differs between species in an <i>in vitro</i> model: implications for preclinical study design. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1000-1004.	3.0	6
4	Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0217621.	3.2	7
5	Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM. <i>AIDS and Behavior</i> , 2022, 26, 3311-3324.	2.7	3
6	Antiretroviral drug exposure in lymph nodes is heterogeneous and drug dependent. <i>Journal of the International AIDS Society</i> , 2022, 25, e25895.	3.0	8
7	The <i>ex vivo</i> pharmacology of HIV-1 antiretrovirals differs between macaques and humans. <i>IScience</i> , 2022, , 104409.	4.1	4
8	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naïve Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). <i>Clinical Infectious Diseases</i> , 2021, 73, e1991-e1999.	5.8	10
9	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	2.5	21
10	The Lymph Node Reservoir: Physiology, HIV Infection, and Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 918-927.	4.7	19
11	Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 725-735.	1.1	4
12	S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1349-1356.	1.9	1
13	Pregnancy-Related Hormones Increase UGT1A1-Mediated Labetalol Metabolism in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , 2021, 12, 655320.	3.5	16
14	Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
15	A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2890-2893.	3.0	0
16	Food Insecurity Is Associated With Lower Levels of Antiretroviral Drug Concentrations in Hair Among a Cohort of Women Living With Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2020, 71, 1517-1523.	5.8	17
17	Antiretroviral Penetration and Drug Transporter Concentrations in the Spleens of Three Preclinical Animal Models and Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
18	Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. <i>Molecular Pharmaceutics</i> , 2020, 17, 3794-3812.	4.6	9

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2020, 11, 579158.	4.8	4
20	Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
21	Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. <i>Clinical and Translational Science</i> , 2020, 13, 777-784.	3.1	14
22	Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	6
23	Disparate effects of Cytotoxic Chemotherapy on the Antiviral Activity of Antiretroviral Therapy: Implications for Treatments of HIV-Infected Cancer Patients. <i>Antiviral Therapy</i> , 2019, 24, 177-186.	1.0	5
24	Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 360-368.	2.5	19
25	Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval—Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection. <i>Pharmacotherapy</i> , 2019, 39, 899-911.	2.6	1
26	Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring. <i>Analytical Chemistry</i> , 2019, 91, 10816-10822.	6.5	17
27	Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	38
28	Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. <i>Nature Communications</i> , 2019, 10, 4324.	12.8	92
29	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	3.1	5
30	HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity. <i>Journal of NeuroVirology</i> , 2019, 25, 560-577.	2.1	27
31	Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2019, 69, 2201-2204.	5.8	37
32	Contemporary Drug-Drug Interactions in HIV Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1362-1377.	4.7	16
33	Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	15
34	Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40). <i>Clinical Infectious Diseases</i> , 2019, 69, 1403-1409.	5.8	10
35	Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. <i>Xenobiotica</i> , 2019, 49, 1192-1201.	1.1	30
36	Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1059-1074.	3.5	23

#	ARTICLE	IF	CITATIONS
37	Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 308-313.	2.1	12
38	Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 40-45.	2.8	21
39	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6652.	2.1	4
40	Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7773-7781.	3.7	7
41	Ultra-long-acting removable drug delivery system for HIV treatment and prevention. <i>Nature Communications</i> , 2018, 9, 4156.	12.8	70
42	Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	49
43	Virological and Immunological Responses to Raltegravir and Dolutegravir in the Gut-Associated Lymphoid Tissue of HIV-Infected Men and Women. <i>Antiviral Therapy</i> , 2018, 23, 495-504.	1.0	6
44	Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10456.	3.7	43
45	HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 513-523.	1.1	27
46	Multimodal analysis of drug transporter expression in gastrointestinal tissue. <i>Aids</i> , 2017, 31, 1669-1678.	2.2	11
47	Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1731-1740.	3.0	50
48	Darunavir for use in pregnant women with HIV. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1317-1327.	3.1	6
49	Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 185-193.	2.0	39
50	Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+T cells. <i>Scientific Reports</i> , 2017, 7, 17697.	3.3	10
51	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. <i>Clinical and Translational Science</i> , 2017, 10, 443-454.	3.1	55
52	A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. <i>PLoS Pathogens</i> , 2017, 13, e1006358.	4.7	25
53	Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable. <i>Pharmaceutical Research</i> , 2016, 33, 1998-2009.	3.5	12
54	A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. <i>Journal of Infectious Diseases</i> , 2016, 214, 55-64.	4.0	251

#	ARTICLE	IF	CITATIONS
55	Analysis of Antiretrovirals in Single Hair Strands for Evaluation of Drug Adherence with Infrared-Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging. <i>Analytical Chemistry</i> , 2016, 88, 1336-1344.	6.5	40
56	HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. <i>Journal of Infectious Diseases</i> , 2016, 214, 1512-1519.	4.0	24
57	Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, e8-e10.	2.1	7
58	Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection. <i>World Journal of Hepatology</i> , 2016, 8, 368.	2.0	1
59	Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract. <i>Antiviral Therapy</i> , 2015, 20, 795-803.	1.0	6
60	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 510-514.	2.1	6
61	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 264-269.	2.1	67
62	Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. <i>Nature Reviews Microbiology</i> , 2015, 13, 414-425.	28.6	179
63	Mass Spectrometry Imaging Reveals Heterogeneous Efavirenz Distribution within Putative HIV Reservoirs. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2944-2948.	3.2	67
64	Quantitative mass spectrometry imaging of emtricitabine in cervical tissue model using infrared matrix-assisted laser desorption electrospray ionization. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 2073-2084.	3.7	66
65	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. <i>Clinical Infectious Diseases</i> , 2015, 61, 120-128.	5.8	17
66	Pharmacokinetics of antiretrovirals in mucosal tissue. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 893-905.	3.3	30
67	Co-localized confocal Raman spectroscopy and optical coherence tomography (CRS-OCT) for depth-resolved analyte detection in tissue. <i>Biomedical Optics Express</i> , 2015, 6, 2022.	2.9	29
68	Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7762-7770.	3.2	15
69	Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6395-6401.	3.2	7
70	A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. <i>PLoS ONE</i> , 2014, 9, e106196.	2.5	28
71	Transport and Transport Properties of Tenofovir from Microbicide Gels into Vaginal Tissue: Analysis Using Raman Spectroscopy. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A59-A60.	1.1	5
72	Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 574-583.	2.0	42

#	ARTICLE	IF	CITATIONS
73	Short Communication: Cheminformatics Analysis to Identify Predictors of Antiviral Drug Penetration into the Female Genital Tract. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1058-1064.	1.1	14
74	Topical microbicides and HIV prevention in the female genital tract. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 603-615.	2.0	21
75	FEM-PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 324-331.	2.1	139
76	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1916-1920.	4.0	13
77	Female Sex Hormone Regulation of Tenofovir-diphosphate in Human Female Reproductive Tract (FRT) Cells in Culture. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A149-A150.	1.1	2
78	Population Pharmacokinetic Model of Vaginal Tenofovir 1% Gel in the Cervicovaginal Fluid. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A38-A38.	1.1	5
79	Predicting Effective Truvada <sup>®</sup> PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A60-A60.	1.1	6
80	Mapping Antiretroviral Drugs in Tissue by IR-MALDESI MSI Coupled to the Q Exactive and Comparison with LC-MS/MS SRM Assay. <i>Journal of the American Society for Mass Spectrometry</i> , 2014, 25, 2038-2047.	2.8	44
81	Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention. <i>Clinical Pharmacokinetics</i> , 2014, 53, 611-624.	3.5	46
82	Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture. <i>PLoS ONE</i> , 2014, 9, e100863.	2.5	26
83	Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study. <i>PLoS ONE</i> , 2014, 9, e111507.	2.5	29
84	Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies. <i>PLoS ONE</i> , 2014, 9, e114368.	2.5	4
85	Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir. <i>Clinical Pharmacokinetics</i> , 2013, 52, 981-994.	3.5	206
86	HIV pre-exposure prophylaxis trials: the road to success. <i>Clinical Investigation</i> , 2013, 3, 295-308.	0.0	16
87	An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. <i>PLoS Pathogens</i> , 2013, 9, e1003834.	4.7	360
88	Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 784-788.	3.2	15
89	Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 260-266.	2.1	37
90	Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 39-44.	2.1	48

#	ARTICLE	IF	CITATIONS
91	Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. <i>Antiviral Therapy</i> , 2013, 18, 1005-1013.	1.0	32
92	Quantitative Analysis of Microbicide Concentrations in Fluids, Gels and Tissues Using Confocal Raman Spectroscopy. <i>PLoS ONE</i> , 2013, 8, e85124.	2.5	27
93	Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2012, 367, 411-422.	27.0	1,377
94	Pre-exposure prophylaxis for HIV prevention: how to predict success. <i>Lancet, The</i> , 2012, 379, 2409-2411.	13.7	64
95	Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission. <i>Science Translational Medicine</i> , 2011, 3, 112re4.	12.4	310
96	Plasma Bile Acid Concentrations in Patients with Human Immunodeficiency Virus Infection Receiving Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity. <i>Pharmacotherapy</i> , 2010, 30, 17-24.	2.6	17
97	Drug Interactions with New and Investigational Antiretrovirals. <i>Clinical Pharmacokinetics</i> , 2009, 48, 211-241.	3.5	73
98	Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. <i>Aids</i> , 2007, 21, 1899-1907.	2.2	177
99	Authors' response: Poor correlation between 6 $\beta$ -hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 633-633.	2.4	0
100	Mechanisms of Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Ritonavir-Enhanced Tipranavir. <i>Pharmacotherapy</i> , 2007, 27, 888-909.	2.6	43
101	Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. <i>Aids</i> , 2005, 19, 145-152.	2.2	53
102	Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 1034-1040.	2.1	91
103	Can Antiretroviral Therapy Be Used to Prevent Sexual Transmission of Human Immunodeficiency Virus Type 1?. <i>Clinical Infectious Diseases</i> , 2002, 34, 1391-1395.	5.8	62
104	Pharmacogenetics of psychotropic drug metabolism. , 2002, , 157-180.		3
105	Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 623-629.	3.2	349
106	Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 403-410.	5.7	66